Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Margolis

Showing results (61-70 of 114) with videos related to

Pageof 12
Sort By:
HIV Research & Clinical Practice|September 20, 2019
Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 studyMiranda Murray, Federico Pulido, Anthony Mills, et al.
AIDS Research and Human Retroviruses|December 16, 2020
Feasibility of Implementing Long-Acting Injectable Antiretroviral Therapy to Treat HIV: A Survey of Health Providers from the 13 Countries Participating in the ATLAS-2M TrialDeanna Kerrigan, Miranda Murray, Tahilin Sanchez Karver, et al.
The Gerontologist|July 10, 2009
Use of pressure-redistributing support surfaces among elderly hip fracture patients across the continuum of care: adherence to pressure ulcer prevention guidelinesMona Baumgarten, David Margolis, Denise Orwig, et al.
The Journal of Antimicrobial Chemotherapy|May 4, 2020
Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravirParul Patel, Zhengyu Xue, Karen S King, et al.
Plos One|January 6, 2018
Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and SpainDeanna Kerrigan, Andrea Mantsios, Miguel Gorgolas, et al.
Journal of Clinical Laser Medicine & Surgery|January 7, 2003
NASA light-emitting diodes for the prevention of oral mucositis in pediatric bone marrow transplant patientsHarry T Whelan, James F Connelly, Brian D Hodgson, et al.
Frontiers in Pharmacology|September 23, 2022
Randomized, placebo-controlled, single-blind phase 1 studies of the safety, tolerability, and pharmacokinetics of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies with an extended half-life in healthy adultsXiaohua Hao, Zheng Zhang, Ji Ma, et al.
Virology|December 11, 2012
Snapshots: chromatin control of viral infectionDavid M Knipe, Paul M Lieberman, Jae U Jung, et al.
The EMBO Journal|April 3, 2002
GCAP1 rescues rod photoreceptor response in GCAP1/GCAP2 knockout miceKim A Howes, Mark E Pennesi, Izabela Sokal, et al.
Lancet (London, England)|January 12, 2013
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 studyFrancois Raffi, Anita Rachlis, Hans-Jürgen Stellbrink, et al.
Pageof 12

Showing results (61-70 of 114) with videos related to

Sort By:
Pageof 12
HIV Research & Clinical Practice|September 20, 2019
Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 studyMiranda Murray, Federico Pulido, Anthony Mills, et al.
AIDS Research and Human Retroviruses|December 16, 2020
Feasibility of Implementing Long-Acting Injectable Antiretroviral Therapy to Treat HIV: A Survey of Health Providers from the 13 Countries Participating in the ATLAS-2M TrialDeanna Kerrigan, Miranda Murray, Tahilin Sanchez Karver, et al.
The Gerontologist|July 10, 2009
Use of pressure-redistributing support surfaces among elderly hip fracture patients across the continuum of care: adherence to pressure ulcer prevention guidelinesMona Baumgarten, David Margolis, Denise Orwig, et al.
The Journal of Antimicrobial Chemotherapy|May 4, 2020
Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravirParul Patel, Zhengyu Xue, Karen S King, et al.
Plos One|January 6, 2018
Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and SpainDeanna Kerrigan, Andrea Mantsios, Miguel Gorgolas, et al.
Journal of Clinical Laser Medicine & Surgery|January 7, 2003
NASA light-emitting diodes for the prevention of oral mucositis in pediatric bone marrow transplant patientsHarry T Whelan, James F Connelly, Brian D Hodgson, et al.
Frontiers in Pharmacology|September 23, 2022
Randomized, placebo-controlled, single-blind phase 1 studies of the safety, tolerability, and pharmacokinetics of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies with an extended half-life in healthy adultsXiaohua Hao, Zheng Zhang, Ji Ma, et al.
Virology|December 11, 2012
Snapshots: chromatin control of viral infectionDavid M Knipe, Paul M Lieberman, Jae U Jung, et al.
The EMBO Journal|April 3, 2002
GCAP1 rescues rod photoreceptor response in GCAP1/GCAP2 knockout miceKim A Howes, Mark E Pennesi, Izabela Sokal, et al.
Lancet (London, England)|January 12, 2013
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 studyFrancois Raffi, Anita Rachlis, Hans-Jürgen Stellbrink, et al.
Pageof 12